April 25 (Reuters) - Synlogic Inc:
* SYNLOGIC RECEIVES FAST-TRACK DESIGNATION FOR SYNB1618, A SYNTHETIC BIOTIC™ MEDICINE FOR THE TREATMENT OF PHENYLKETONURIA
* SYNLOGIC INC - PHASE 1/2A CLINICAL STUDY OF SYNB1618 EXPECTED TO REPORT INTERIM DATA IN 2018 Source text for Eikon: Further company coverage:
